S Oliva et al. Clinical Gastroenterology and Hepatology; 2026 (Epub, 9/7/26). Open Access! Long-Term Effectiveness of Dupilumab in Eosinophilic Esophagitis: Results From the DUPEOETALY Study
Methods: This retrospective observational study included 167 patients, median age, 21.5 years, with EoE from 50 Italian centers, unresponsive or intolerant to conventional therapies. Given the real-world design of the study, no standardized protocol mandated patient re-evaluation at fixed follow-up timepoints. Histologic remission was considered having <15 eos/hpf. All patients, however, underwent at least 3 endoscopic assessments: at baseline, after the induction phase (performed between weeks 12 and 24), and at 1-year follow-up. At baseline, 76% had a personal history of atopy, 86.2% had used corticosteroids, and 94% had used proton pump inhibitors.
Key findings:
- DSQ score decreased from 22.14 ± 26.63 to 0.21 ± 2.30, EREFS from 4.95 ± 3.43 to 0.07 ± 0.09, and Eos/HPF from 36.80 ± 31.75 to 0.06 ± 0.46.
- Improvements increased with treatment duration. By week 72, 98.3% of patients achieved remission criteria (DSQ ≤5, Eos/HPF ≤15, and EREFS ≤2).
- No serious or systemic adverse events were reported, and no patients discontinued treatment due to intolerance.
with complete remission achieved when all 3 were met simultaneously.24
Discussion:
- “Only a small proportion of patients in our cohort had a history of esophageal dilation (8.4%), which may suggest a relatively lower burden of advanced fibrostenotic disease…could partially influence remission rates and should be considered when interpreting the generalizability of our findings to populations with more severe structural disease.”
My take: This study supports the long-term effectiveness of dupilumab in pediatric and adult patients with EoE. It is not clear why there was such a high remission rate in this cohort compared to previous reports.
Related blog posts:
Some good brief YouTube EoE educational videos for families from GIKids.org (with pharmaceutical funding), links:
